This company listing is no longer active
ImmunoPrecise Antibodies Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Información clave
-25.6%
Tasa de crecimiento de los beneficios
-0.6%
Tasa de crecimiento del BPA
| Crecimiento de la industria Life Sciences | 26.8% |
| Tasa de crecimiento de los ingresos | 28.7% |
| Rentabilidad financiera | -34.5% |
| Margen neto | -117.4% |
| Última actualización de beneficios | 31 Jul 2022 |
Actualizaciones de resultados anteriores recientes
Desglose de ingresos y gastos
Cómo gana y gasta dinero ImmunoPrecise Antibodies. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Jul 22 | 19 | -23 | 19 | 11 |
| 30 Apr 22 | 19 | -17 | 18 | 7 |
| 31 Jan 22 | 19 | -17 | 16 | 6 |
| 31 Oct 21 | 19 | -15 | 16 | 5 |
| 31 Jul 21 | 19 | -10 | 15 | 3 |
| 30 Apr 21 | 18 | -7 | 13 | 2 |
| 31 Jan 21 | 17 | -3 | 12 | 1 |
| 31 Oct 20 | 17 | -3 | 10 | 1 |
| 31 Jul 20 | 15 | -3 | 9 | 1 |
| 30 Apr 20 | 14 | -5 | 9 | 0 |
| 31 Jan 20 | 13 | -8 | 9 | 1 |
| 31 Oct 19 | 11 | -8 | 9 | 1 |
| 31 Jul 19 | 11 | -9 | 9 | 1 |
| 30 Apr 19 | 11 | -8 | 9 | 0 |
| 31 Jan 19 | 10 | -6 | 9 | 1 |
| 31 Oct 18 | 9 | -6 | 9 | 0 |
| 31 Jul 18 | 8 | -5 | 8 | 0 |
| 30 Apr 18 | 5 | -5 | 6 | 1 |
| 31 Jan 18 | 4 | -4 | 5 | 1 |
| 31 Oct 17 | 3 | -7 | 4 | 1 |
| 31 Jul 17 | 2 | -6 | 2 | 1 |
| 30 Apr 17 | 3 | -5 | 2 | 1 |
| 31 Jan 17 | 3 | -4 | 1 | 0 |
| 31 Oct 16 | 3 | 1 | 1 | 0 |
| 31 Jul 16 | 2 | 0 | 1 | 0 |
| 30 Apr 16 | 2 | 0 | 1 | 0 |
Ingresos de calidad: IPA is currently unprofitable.
Margen de beneficios creciente: IPA is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: IPA is unprofitable, and losses have increased over the past 5 years at a rate of 25.6% per year.
Acelerando crecimiento: Unable to compare IPA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: IPA is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (14.4%).
Rentabilidad financiera
Alta ROE: IPA has a negative Return on Equity (-34.51%), as it is currently unprofitable.